Skip to Main Content

Early Detection and Prevention Guidelines for Cervical Cancer

Date: 04/08/24

In 2024, the American Cancer Society estimates 13,820 cases of cervical cancer will be diagnosed in the US and about 4,360 women will die from cervical cancer. Almost all cervical cancers are caused by persistent infection with certain types of human papillomavirus (HPV). Half of those diagnosed with cervical cancer have never been screened. When detected early, cervical cancer is one of the most successfully-treatable cancers.

Regular Pap testing is the most reliable and effective way to screen for cervical cancer. Early detection can help avoid delays in diagnosis and increase the chances of successful treatment.  It can also prevent pre-cancer from turning into cervical cancer.

The HPV vaccination can also protect children, teens and young adults against infection from certain types of HPV and some cancers linked to those types. The vaccination can help prevent infection from HPV-16 and HPV-18 which cause most cervical cancers, precancers, as well as cancers of the anus, penis, vulva, vagina and throat.

Providers can help Superior members by educating them on the early HPV detection and vaccination methods outlined in the tables below.

HPV Testing

AGE

PAP/HUMAN PAPILLOMA VIRUS (HPV) TESTS

Females, 25 - 65 years of age

HPV testing every 5 years

OR

If primary HPV testing is not available, screening may be done that combines HPV test with Pap test every 5 years

OR

Pap test every 3 years

Females, –over 65 years of age

Stop cervical cancer screening for those who have had regular screenings for 10 years with normal results and no history of serious diagnosis within the past 25 years

 

HPV Vaccinations 

AGE

TYPE OF VACCINATION

SECOND DOSE

THIRD DOSE

All members, 9 - 14 years of age

2-dose vaccination series

Within 6-12 months after the initial dose

N/A

All members, 15 - 26 years of age

3-dose vaccination series

Within 1-2 months after the initial dose, at minimum 4 weeks between 1st and 2nd dose

Within 6 months after the first dose, at minimum at least 12 weeks between 2nd and 3rd dose, and 5 months between 1st and 3rd dose

Immunocompromised persons (including those with HIV infection), aged 9 – 26 years of age

3-dose vaccination series

Within 1-2 months after the initial dose, at minimum 4 weeks between 1st and 2nd dose

Within 6 months after the first dose, at minimum at least 12 weeks between 2nd and 3rd dose

Please note: Women who have been vaccinated for HPV will still need regular Pap tests.

For additional information on the guidelines above, please visit Superior’s Immunization Toolkit.

Superior reports annually on the percentage of members, 21 to 64 years of age, who were recommended for a routine cervical cancer screening and were screened for cervical cancer. Superior also reports on the percentage of adolescents who have turned 13 years of age and have completed the HPV vaccine series on or between their 9th and 13th birthdays.

To see more information on the stats and guidelines mentioned above, or find more information on cervical cancer screenings, please visit the American Cancer Society Cervical Cancer Prevention webpage. For information on HPV vaccinations please visit the Center for Disease Control and Prevention HPV Vaccine Schedule and Dosing webpage.